Biomotif AB

Biomotif is a R&D, CRO and instrument sales company with technology for analyzing complex biological samples. We have new powerful tools for modern drug development and validation of new drug candidates.
Biomotif develop new front end instrumentation for mass spectrometry. The multifunctional proprietary HX-IA Instrument™ has been developed for advanced PROTEOMICS & INTERACTOMICSstudies. This technology is based on several new inventions such as ElectroCapture, Memrane assisted H/DX, Compound Fishing-Epitope Imprinting and on-line pI separation of proteins and peptides.

The HX-IA Instrument™ will provide a better understanding of biomarker targets and there structure/conformation, dynamics and molecular interactions with potential drug candidates in the liquid phase.

Biomotif offer a contract analysis service in the following areas:

HDX Studies-Mode-of-Action (MoA) analysis

Drug Discovery – Small Molecule and Antibody –

  • Protein-antibody epitope mapping identification
  • Protein-protein or protein-peptide interface mapping
  • Bioequivalence studies
  • Patent submission/protection information
  • H/DX screening for structure based drug design

Structural Biology

  • Identification of disordered regions in protein constructs that prevent crystallization
  • Identifying the effect of mutations on protein stability
  • Complementary data to x-ray and NMR data

Scientific Collaboration Partners
We will work with world class scientific partners for technology and method development. Our partners will get access to unique technology for solving complicated analytical tasks as well as copublish with us in high end scientific journals.

The substance library is based upon the active site of the protease inhibitor Cystatin C
ZULA Diagnostics AB, a company located in Täby, Sweden, has the most promising innovation based on unique new substances, arginine derivatives, for research collaboration, project partnering and out-licensing.

More than 25 years of intensive research on the human protein Cystatin C, including identification of its biological active site has lead to production of a large number of small (

ZULA have potent Antibiotic and Antiviral drug candidates based on the elucidation of the structure of the active site of a human protein, Cystatin C.

The mechanism is different compared to all currently available antibiotics, since bacterial strains resistant against all presently available antibiotics still are killed.

Some of our substances show antiviral capability to inhibit the replication of both DNA virus e.g. Herpes simplex and RNA virus e.g. Polio.

We are seeking financial partners for the development and testing of these drug candidates.

ZULA provides high throughput proteomics analyses of clinical samples, first of all blood plasma.

By fast and accurate profiling the relative concentrations of abundant proteins, stratification of patients is performed that is predictive of the progression of Alzheimer’s disease (AD) as well as other severe diseases. Unlike our competitors who search for (often elusive and sometimes non-existent) “golden” molecules uniquely identifying disease status, our approach is to utilize easily accessible information coded in small variations of the levels of abundant proteins. This approach is fast, requires minute amounts of sample, and is potentially scalable to be incorporated in the highthroughput blood analysis pipeline of major hospital centers.

ZULA conducts research related to the action mechanism of novel as well as known anticancer and antibacterial agents. Rapid “in-silico” mechanism prediction algorithm is used to forecast the best complementary drugs for known anticancer agents.

ZULA will initially explore the unique properties of one of the substances in a new cosmetic product, a Lip Balm, for skin and lips in bad condition.

With a special formulation containing exclusive Swedish and Nordic natural ingredients together with Arginine derivative A20, we plan to market our product as a “Swedish Magic Cream”.

ZuLa Diagnostics AB
P. O. Box 156, SE-182 12 Danderyd
Tel.: +46 70 563 89 53
Biomotif AB
+46 8 755 43 90